Todd Harris - Nov 2, 2021 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Chief Executive Officer, Director
Signature
/s/ John Healy, Attorney-in-Fact
Stock symbol
TYRA
Transactions as of
Nov 2, 2021
Transactions value $
$0
Form type
4
Date filed
11/4/2021, 07:39 PM
Previous filing
Sep 17, 2021
Next filing
Sep 8, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Stock Option (Right to Buy) Award $0 +215K $0.00 215K Nov 2, 2021 Common Stock 215K $24.15 Direct F1
transaction TYRA Stock Option (Right to Buy) Award $0 +25.9K $0.00 25.9K Nov 2, 2021 Common Stock 25.9K $24.15 Direct F2
transaction TYRA Stock Option (Right to Buy) Award $0 +25.9K $0.00 25.9K Nov 2, 2021 Common Stock 25.9K $24.15 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares subject to the option vest monthly following November 2, 2021, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
F2 The option vests based on achievement of a performance objective.